Teriflunomide, a once-daily, oral disease-modifying therapy, has demonstrated 
efficacy in patients with relapsing forms of multiple sclerosis (MS) and 
patients with a first clinical episode suggestive of MS. As the only 
disease-modifying therapy with positive disability results in two Phase III 
trials, teriflunomide significantly slowed disability in patients with relapsing 
forms of MS. We highlight data from the Phase II study and the TEMSO, TOWER, 
TOPIC and TENERE teriflunomide studies. TEMSO MRI outcomes have been supported 
with Structural Image Evaluation Using Normalization of Atrophy analyses. We 
present data from long-term extensions of the Phase II study, TEMSO and TOWER, 
as well as results from patients who switched from other disease-modifying 
therapies to teriflunomide, patient-reported outcomes and supplementary measures 
of response.